

Lorenzo Marconi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/179968/publications.pdf>

Version: 2024-02-01

46
papers

6,752
citations

201385

27
h-index

264894

42
g-index

46
all docs

46
docs citations

46
times ranked

6956
citing authors

#	ARTICLE	IF	CITATIONS
1	2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma. <i>European Urology</i> , 2022, 81, 134-137.	0.9	29
2	Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results >2,000 patients in 41 countries, with focus on older patients.. <i>Journal of Clinical Oncology</i> , 2022, 40, 306-306.	0.8	1
3	European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. <i>European Urology</i> , 2022, 82, 399-410.	0.9	485
4	Surgical margins after partial nephrectomy as prognostic factor for the risk of local recurrence in pT1 RCC: a systematic review and narrative synthesis. <i>World Journal of Urology</i> , 2022, 40, 2169-2179.	1.2	8
5	The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgeryâ€”Results from RECUR Consortium. <i>European Urology Oncology</i> , 2021, 4, 473-482.	2.6	33
6	Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma. <i>European Urology</i> , 2021, 79, 339-342.	0.9	98
7	Should patients with low-risk renal cell carcinoma be followed differently after nephron-sparing surgery vs radical nephrectomy?. <i>BJU International</i> , 2021, 128, 386-394.	1.3	5
8	Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e92-e99.	0.9	30
9	Early morning kidney transplantation: Perioperative complications. <i>Archivio Italiano Di Urologia Andrologia</i> , 2021, 93, 158-161.	0.4	0
10	The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naïve Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care. <i>European Urology</i> , 2021, 80, 393-397.	0.9	103
11	Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel. <i>European Urology Oncology</i> , 2020, 3, 57-72.	2.6	62
12	Limitations of Available Studies Prevent Reliable Comparison Between Tumour Ablation and Partial Nephrectomy for Patients with Localised Renal Masses: A Systematic Review from the European Association of Urology Renal Cell Cancer Guideline Panel. <i>European Urology Oncology</i> , 2020, 3, 433-452.	2.6	43
13	Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma. <i>European Urology</i> , 2019, 76, 151-156.	0.9	190
14	Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. <i>European Urology</i> , 2019, 76, 27-30.	0.9	53
15	Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.). <i>Scandinavian Journal of Urology</i> , 2019, 53, 14-20.	0.6	15
16	European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. <i>European Urology</i> , 2019, 75, 799-810.	0.9	1,022
17	Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR). <i>European Urology</i> , 2019, 75, 261-264.	0.9	30
18	Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis. <i>European Urology Focus</i> , 2019, 5, 857-866.	1.6	67

#	ARTICLE	IF	CITATIONS
19	Prevalence, disease-free (DFS) and overall (OS) survival of contemporary high-risk renal cell carcinoma (RCC) patients eligible for adjuvant checkpoint inhibitor trials: A RECUR database analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 636-636.	0.8	2
20	Risks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer: A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel. <i>European Urology</i> , 2018, 74, 76-83.	0.9	61
21	Key Steps in Conducting Systematic Reviews for Underpinning Clinical Practice Guidelines: Methodology of the European Association of Urology. <i>European Urology</i> , 2018, 73, 290-300.	0.9	128
22	Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer. <i>European Urology</i> , 2018, 73, 311-315.	0.9	138
23	Robotic Partial Nephrectomy for Posterior Renal Tumours: Retro or Transperitoneal Approach?. <i>European Urology Focus</i> , 2018, 4, 632-635.	1.6	19
24	A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations. <i>European Urology</i> , 2018, 74, 849-851.	0.9	3
25	Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma. <i>European Urology</i> , 2018, 74, 805-809.	0.9	80
26	Follow-up after curative treatment of localised renal cell carcinoma. <i>World Journal of Urology</i> , 2018, 36, 1953-1959.	1.2	31
27	Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. <i>European Urology</i> , 2018, 74, 611-620.	0.9	77
28	External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>World Journal of Urology</i> , 2018, 36, 1973-1980.	1.2	10
29	Imaging modalities used for follow-up of localized renal cell carcinoma (RCC) and subsequent effect on overall survival after recurrence: RECUR-database analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 637-637.	0.8	2
30	Conflict of Evidence: Resolving Discrepancies When Findings from Randomized Controlled Trials and Meta-analyses Disagree. <i>European Urology</i> , 2017, 71, 811-819.	0.9	23
31	Reply to Philipp Dahm, Vikram Narayan, and Jae Hung Jung's Letter to the Editor re: Richard J. Sylvester, Steven E. Canfield, Thomas B.L. Lam, et al. Conflict of Evidence: Resolving Discrepancies When Findings from Randomized Controlled Trials and Meta-analyses Disagree. <i>Eur Urol</i> 2017;71:811–9. <i>European Urology</i> , 2017, 72, e93-e94.	0.9	0
32	What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. <i>European Urology</i> , 2017, 72, 250-266.	0.9	305
33	A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2017, 71, 426-436.	0.9	123
34	Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma. <i>European Urology</i> , 2017, 71, 719-722.	0.9	69
35	Re: Maria Carmen Mir, Ithaar Derweesh, Francesco Porpiglia, Homayoun Zargar, Alexandre Mottrie, Riccardo Autorino. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. <i>Eur Urol</i> . 2017;71:606–17. <i>European Urology</i> , 2017, 72, e59-e60.	0.9	0
36	European Association of Urology (EAU) guidelines: do we care? Reflections from the EAU Impact Assessment of Guidelines Implementation and Education group. <i>BJU International</i> , 2016, 117, 850-851.	1.3	6

#	ARTICLE	IF	CITATIONS
37	Renal Preservation and Partial Nephrectomy: Patient and Surgical Factors. <i>European Urology Focus</i> , 2016, 2, 589-600.	1.6	71
38	Reply to E. Jason Abel Letter to the Editor re: Lorenzo Marconi, Saeed Dabestani, Thomas B. Lam, et al. Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. <i>Eur Urol</i> 2016;69:660-673. <i>European Urology</i> , 2016, 69, e119-e120.	0.9	5
39	Reply to Jae Heon Kim's Letter to the Editor re: Lorenzo Marconi, Saeed Dabestani, Thomas B. Lam, et al. Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. <i>Eur Urol</i> 2016;69:660-673. <i>European Urology</i> , 2016, 70, e141-e142.	0.9	0
40	European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy. <i>European Urology</i> , 2016, 70, 705-706.	0.9	34
41	Systematic Review of Surgical Management of Nonmetastatic Renal Cell Carcinoma with Vena Caval Thrombus. <i>European Urology</i> , 2016, 70, 265-280.	0.9	81
42	Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy. <i>European Urology</i> , 2016, 69, 4-6.	0.9	85
43	Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. <i>European Urology</i> , 2016, 69, 660-673.	0.9	412
44	EAU Guidelines on Renal Cell Carcinoma: 2014 Update. <i>European Urology</i> , 2015, 67, 913-924.	0.9	2,445
45	Post Partial Nephrectomy Surveillance Imaging: an Evidence-Based Approach. <i>Current Urology Reports</i> , 2015, 16, 23.	1.0	3
46	Local treatments for metastases of renal cell carcinoma: a systematic review. <i>Lancet Oncology</i> , The, 2014, 15, e549-e561.	5.1	265